Omnicell Inc. (NASDAQ:OMCL) has received a consensus rating of “Buy” from the nine ratings firms that are currently covering the stock. Three analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $37.71.
A number of equities research analysts have recently weighed in on the company. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $46.00 price target on shares of Omnicell in a report on Tuesday, September 13th. Sidoti downgraded Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 price target for the company. in a report on Thursday, September 8th. Zacks Investment Research downgraded Omnicell from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 3rd. Finally, FBR & Co boosted their price target on Omnicell from $40.00 to $41.00 and gave the company an “outperform” rating in a report on Friday, July 29th.
In other Omnicell news, EVP Robin Gene Seim sold 3,645 shares of the business’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $35.00, for a total transaction of $127,575.00. Following the completion of the transaction, the executive vice president now owns 55,420 shares in the company, valued at approximately $1,939,700. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gary S. Petersmeyer sold 2,000 shares of the business’s stock in a transaction on Monday, September 12th. The stock was sold at an average price of $37.98, for a total value of $75,960.00. Following the transaction, the director now owns 17,987 shares of the company’s stock, valued at approximately $683,146.26. The disclosure for this sale can be found here. Company insiders own 3.75% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Fund Advisors raised its position in shares of Omnicell by 4.6% in the second quarter. BlackRock Fund Advisors now owns 2,442,492 shares of the company’s stock worth $83,607,000 after buying an additional 107,068 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Omnicell by 2.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,761,467 shares of the company’s stock worth $60,295,000 after buying an additional 40,114 shares during the period. Vanguard Group Inc. raised its position in shares of Omnicell by 4.2% in the second quarter. Vanguard Group Inc. now owns 1,639,227 shares of the company’s stock worth $56,111,000 after buying an additional 65,768 shares during the period. Glenmede Trust Co. NA raised its position in shares of Omnicell by 4.1% in the second quarter. Glenmede Trust Co. NA now owns 1,053,320 shares of the company’s stock worth $36,053,000 after buying an additional 41,957 shares during the period. Finally, Royal Bank of Canada raised its position in shares of Omnicell by 0.8% in the first quarter. Royal Bank of Canada now owns 685,223 shares of the company’s stock worth $19,097,000 after buying an additional 5,387 shares during the period. Institutional investors own 95.26% of the company’s stock.
Omnicell (NASDAQ:OMCL) opened at 37.83 on Monday. The firm has a 50-day moving average price of $37.85 and a 200 day moving average price of $33.24. The stock has a market cap of $1.37 billion, a PE ratio of 96.02 and a beta of 0.69. Omnicell has a 52-week low of $25.06 and a 52-week high of $40.50.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.38 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.32 by $0.06. Omnicell had a return on equity of 10.41% and a net margin of 2.36%. The business earned $175.60 million during the quarter, compared to the consensus estimate of $170.89 million. During the same period in the previous year, the business earned $0.28 EPS. The business’s quarterly revenue was up 55.7% on a year-over-year basis. Equities analysts anticipate that Omnicell will post $1.58 earnings per share for the current year.
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.